ARCHIVES

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

UPCI To Lead Clinical Trials Of Eli Lilly’s Oncology Agents.

July 6, 2001

Definitions, New Categories Of Centers Suggested By Cantril

July 2, 1976

Bristol-Myers Cancer Scientist Award Nominations To Close March 1

February 24, 1978

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

In Brief: Patterns Of care Study Leads “Part Tie” Radiotherapists To Drop Out, Sheline Says

July 22, 1977

ACCC Honors Hammond, Murphy

October 19, 2001